Posted: 7 month(s) and 1 days(s) ago   |   0 Comment(s)   |   Rating: 0 0
Posted by: ToddShriber

Quigley Corp. (QGLY.NSDQ), the drug delivery company that I mentioned a couple of weeks ago after a solid earnings report, fell 47 cents, or 17%, to $2.35 today, making the stock the top loser on the Nasdaq. Volume was right in line with the daily average.

There was no news impacting the stock today, but it is worth noting that big pharma stocks haven't really participated in the recent market rally, so it's hard to get bullish on smaller players like Quigley.

Looking at Quigley's chart, the stock failed miserably above $3 and will likely find support at a downward trendline that rests at $1.75. If the shares fell to that level and no further, then a bounce higher is possible. However, if Quigley violates $1.75, I'd stay away.

For more on Quigley, go here: http://www.quigleyco.com

Add Comment / Rating

Posted: 8 month(s) and 1 days(s) ago   |   0 Comment(s)   |   Rating: 0 0
Posted by: ToddShriber

Zareba Systems (ZRBA.NSDQ), the maker of security systems, rocketed higher by $1.69, or 80%, to $3.79 today, making the stock the top gainer on the Nasdaq. More than 88,000 shares changed hands compared to average daily trade of just 513 shares.

The company said it expects to report a profit of $1.3 million to $1.4 million for the first half of this year compared to a loss of almost $7 million for the year earlier period. Zareba also reduced the amount outstanding under its bank credit facilities to $2.1 million at June 30, 2009 from $4.7 million at the end of fiscal 2008.

Minnesota-based Zareba Systems makes energizers, high tensile fence systems, insulators, poly wire, tape and rope, automatic gate openers, and perimeter security fence systems for human and animal control, containment, detection, and deterrence.

There is something to like here with this stock no debt and over $1.1 million in free cash flow. The Street loves strong balance sheets and so should you. Zareba fits the bill.

For more on Zareba Systems, go here: http://www.ZarebaSystemsInc.com

Add Comment / Rating

Posted: 9 month(s) and 13 days(s) ago   |   0 Comment(s)   |   Rating: 0 0
Posted by: ToddShriber

Jazz Pharmaceuticals (JAZZ.NSDQ) surged $2.14, or 210%, to $3.16 ahead of a Phase III clinical data release for its fibromyalgia treatment candidate sodium oxybate, or JZP-6. The stock was the top gainer on the Nasdaq today as over 18 million shares changed hands compared to average daily volume of less than 58,000.

Jazz hopes to file for approval of the drug by the end of this year. Sodium oxybate is already used to treat sleep disorders, according to press reports.

The Street seems to be anticipating good news and Jazz will present findings later this week so the stock is worth a watch. Any more good news and the stock could definitely surge some more.

Add Comment / Rating

Posted: 9 month(s) and 14 days(s) ago   |   0 Comment(s)   |   Rating: 0 0
Posted by: ToddShriber

MDRNA (MRNA.NSDQ) shot up $1.16, or 75%, to $2.70 after the FDA approved the company's generic version of the osteoporosis treatment Miacalcin. The stock was the biggest gainer on the Nasdaq today.

MDRNA said U.S. sales of Miacalcin totaled $112 million in 2008. Novartis AG makes Miacalcin. MDRNA partners with Par Pharmaceuticals (PRX.NYSE) to make the generic Miacilin.

MDRNA shares had been languishing below $1 for most of 2009, so it will be interesting to see how the stock performs in light of today's news.

Add Comment / Rating